aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser or broker-dealer and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform.

Analysis of China $1.8 Billion Jiangsu Sinopep-Allsino Biopharmaceutical Fined $6.6 Million & Issued with Delisting Warning for Inflating Revenue ($4.2 Million) & Profit ($3.6 Million) in 2021 Which Also Allowed Company to Issue $60 Million Convertible Bonds in 2023, Senior Executives Fined from $209,000 to $2.5 Million with ex-Vice Chairman & Actual Controller Dezhong Zhao Fined $2.5 Million (CNY 18 Million), Founded in 2009 by Zi Quan Tong, IPO on Shanghai Stock Exchange in 2021 - aVenture Research